WO2011149438A1 - Combinaison d'agents antihypertenseurs - Google Patents

Combinaison d'agents antihypertenseurs Download PDF

Info

Publication number
WO2011149438A1
WO2011149438A1 PCT/TR2011/000153 TR2011000153W WO2011149438A1 WO 2011149438 A1 WO2011149438 A1 WO 2011149438A1 TR 2011000153 W TR2011000153 W TR 2011000153W WO 2011149438 A1 WO2011149438 A1 WO 2011149438A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
cellulose
sodium
calcium
Prior art date
Application number
PCT/TR2011/000153
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11729785.3A priority Critical patent/EP2575808A1/fr
Publication of WO2011149438A1 publication Critical patent/WO2011149438A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a combination of antihypertensive active agents; methods for preparation of said combination; and use of said combination in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
  • the present invention relates to use of the active agents a) mdapamide which is a diuretic, b) amlodipine which is a calcium channel blocker and c) telmisartan which is an angiotensin receptor antagonist in combination.
  • Indapamide chemical name of which is 4-chloro-N-(2-methylindolyn-l-yl)-3-sulfamoyl- benzamide, was first disclosed in the patent numbered US 3565911. There exist various processes for preparation of the molecule indapamide and pharmaceutical compositions comprising the active agent indapamide in the prior art. It is known that indapamide is indicated in the treatment of hypertension and edema.
  • Amlodipine chemical name of which is 3-ethyl 5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4- (o-cUorophenyl)-l,4-dmydropyridme-6-memyl-3,5-pyridinedicarboxylate, was disclosed in the patent numbered EP 0089167 in detail.
  • telmisartan The molecule telmisartan, chemical name of which is 4'-[(l,4-dimethyl-2'-propyl[2,6-bi-lH- benzimidazo l]- -yl)meyl]-[l, -biphenyl)-2-carboxylic acid, was disclosed in the patent numbered EP 0502314.
  • telmisartan chemical name of which is 4'-[(l,4-dimethyl-2'-propyl[2,6-bi-lH- benzimidazo l]- -yl)meyl]-[l, -biphenyl)-2-carboxylic acid
  • the present invention relates to combined use of the active agents indapamide (formula I) which is a diuretic; amlodipine (formula II) which is a calcium channel blocker; and telmisartan (formula III) which is an angiotensin receptor antagonist.
  • telmisarta The present invention comprises use of the active agents indapamide, amlodipine and telmisartan in combination. In addition, it also comprises optional use of pharmaceutically acceptable excipients in said composition.
  • the active agents of the combination of the present invention can be in free form or in the forms of pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms and amorphous forms of the respective active agents.
  • the active agent amlodipine in the combination of the present invention is preferably in the form of pharmaceutically acceptable salt thereof.
  • besylate salt of amlodipine which can be in the form of besylate, mesylate or maleate salt, is used.
  • the present invention relates to use of said combination in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
  • hypertension-related diseases and various cardiovascular diseases refers to diseases such as acute and/or chronic heart failure, congestive heart failure, left heart failure, hypertrophic cardiomyopathy, arrhythmia, cardiomegalia, atrial fibrillation, embolism, ischemic heart disease, coronary artery disease, myocardial infarction, atherosclerosis, angina, renal failure, angina pectoris, diabetes, secondary aldosteronism, pulmonary hypertension, diabetic nephropathy, scleroderma, glomerulosclerosis, albuminuria, diabetic retinopathy, migraine, peripheral vascular diseases, Raynaud's phenomenon, cognitive disorders, hypertensive encephalopathy, thrombotic glaucoma and stroke.
  • Pharmaceutical compositions comprising the combination of the present invention can be used simultaneously, sequentially or separately.
  • the active agents of the composition of the present invention can be formulated separately so as to be used in a kit form.
  • the present invention relates to administration of said combination in warm blooded animals in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
  • the present invention relating to use of a pharmaceutical composition to be used in the manufacture of an effective drug for the treatment of hypertension, hypertension related diseases and various cardiovascular diseases is characterized by comprising the active agents indapamide, amlodipine and telmisartan.
  • the composition comprising the active agents telmisartan, amlodipine and indapamide can be prepared to be used by the oral route.
  • compositions of the present invention comprises oral dosage forms and their pharmaceutical formulations which optionally comprise pharmaceutically acceptable excipients in addition to the active agents.
  • Oral dosage forms can be in solid dosage forms such as tablet; capsule; enteric coated or modified release tablets; prolonged release tablet; delayed release tablet; fast soluble tablet; effervescent tablet; effervescent granule; fast soluble powder mixture or dry powder mixture for syrup preparation; dragee; orally disintegrating tablet; water soluble tablet; water soluble powder, tablet or granule; film tablet; or liquid dosage forms such as suspension.
  • the amount of active agent in the formulation of the present invention can vary in the range of 0.5% to 95%, preferably in the range of 1% to 90% in proportion to total amount of substances in the pharmaceutical formulation.
  • Dose of the active agent in the pharmaceutical formulation can vary according to the route of administration; patient's age and state of health.
  • one dose of the pharmaceutical composition comprising the present invention can comprise 10-300 mg telmisartan; 2,5-25 mg amlodipine; 0,1-10 mg indapamide.
  • the composition of the present invention is composed of the active agents telmisartan, amlodipine and indapamide. Desired therapeutic action time is obtained by intake of telmisartan and amlodipine once a day. However, this is not possible for indapamide.
  • the inventors considered to formulate the combination in compressed bilayer tablet form in order to equalize action times of the active agents. Antihypertensive action times of the active agents of the composition can be equalized by comprising indapamide, which has shorter hypertensive action time compared with the other active agents in the composition, both in the fast release layer and the constant release layer. More effective compositions have been obtained by formulating the combination of the present invention in compressed bilayer tablet form.
  • the constant release layer comprising indapamide is the innermost layer of the tablet.
  • Fast release layer comprising telmisartan, amlodipine and indapamide, on the other hand, is placed around the constant release layer.
  • tablet forms are obtained such that the coating is the outermost layer of the tablet.
  • polymers can be used in order to provide constant release of indapamide.
  • Polymers ensuring constant release can be selected from, but not limited to, a group comprising cellulose derivatives, particularly hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, methyl hydroxypropyl cellulose, carboxymethyl cellulose, povidone; acrylic acid copolymers or combinations thereof.
  • compositions comprising the combinations of antihypertensive active agents are produced according to conventional techniques optionally with addition of pharmaceutically acceptable excipients.
  • excipients can also be used in addition to the active agents used in each oral formulation.
  • excipients can be components such as at least one binder, lubricant, disintegrant, demulsifying agent, stabilizing agent, flavoring agent, diluent, surfactant and glidant.
  • binders can be selected from, but not limited to, the group comprising starches (such as potato starch, corn starch, wheat starch); sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums (such as acacia); gelatin; cellulose derivatives (such as macrocrystalline cellulose, HPC, HEC, HPMC, carboxymethyl cellulose, methyl cellulose, ethyl cellulose); povidone, polyvinylpyrrolidone, polyethylene glycol; waxes; calcium carbonate; calcium phosphate; alcohols (such as sorbitol, xylitol, mannitol) and water.
  • starches such as potato starch, corn starch, wheat starch
  • sugars such as sucrose, glucose, dextrose, lactose, maltodextrin
  • natural and synthetic gums such as acacia
  • gelatin such as macrocrystalline cellulose, HPC, HEC, HPMC, carboxy
  • Pharmaceutically acceptable lubricant can be selected from, but not limited to, the group comprising stearic acid, stearic acid salts (calcium state, magnesium stearate, etc.), talc, colloidal silica, wax, boric acid, adipic acid, sulfates (sodium sulfate), glycol, fumaric acid, sodium benzoate, DL-leucine, lauryl sulfate (sodium lauryl sulfate, magnesium lauryl sulfate, etc.), silicates, starch derivatives.
  • Pharmaceutically acceptable disintegrants can be selected from, but not limited to, the group comprising cellulose derivatives (low-substituted hydoxypropyl cellulose, carboxymethylcellulose, calciumcarboxymethylcellulose, cross-linked sodium carboxymethyl cellulose) and chemically modified starch/cellulose derivatives (carboxymethyl starch, sodiumcarboxymethyl starch, etc.).
  • compositionsifying agents can be selected from, but not limited to, the group comprising colloidal clay (bentonite, etc.), metal hydroxides (magnesium hydroxide, aluminum hydroxide, etc.), anionic surfactant (sodium lauryl sulfate, calcium stearate, etc.), cationic surfactant or ionic surfactant (polyoxyethylene alkyl ether, fatty acid ester of polyoxyethylene sorbitan or sucrose esters of fatty acids).
  • colloidal clay bentonite, etc.
  • metal hydroxides magnesium hydroxide, aluminum hydroxide, etc.
  • anionic surfactant sodium lauryl sulfate, calcium stearate, etc.
  • cationic surfactant or ionic surfactant polyoxyethylene alkyl ether, fatty acid ester of polyoxyethylene sorbitan or sucrose esters of fatty acids.
  • Stabilizing agent and/or agents can be selected from agents such as antioxidants, chelating agents, alkalinizing agents and photoprotective agents.
  • Antioxidants can be selected from, but not limited to, the group comprising substances such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium sulfite, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylsistein, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • gallates such as propyl gallate
  • tocopherol citric acid, malic acid, ascorbic acid, acetylsistein, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate.
  • Chelating agents can be selected from, but not limited to, the group comprising disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof.
  • Alkalinizing agents can be selected from, but not limited to, alkali metal salts such as sodium carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines, ⁇ , ⁇ '- dibenzylemylenediamine, diemanolamine, ethylenediamine, meglumine, monosodium glutamate, polacryline sodium, sodium alginate.
  • Photoprotective agents can be selected from, but not limited to, a group comprising metal oxides such as titanium oxide, iron oxide or zinc oxide.
  • Pharmaceutically acceptable flavoring agents can be selected from, but not limited to, the group comprising sour cherry flavor, blackberry flavor, grapefruit flavor, grape flavor, pear flavor, orange flavor, apricot flavor or combinations thereof.
  • Pharmaceutically acceptable diluents can be selected from, but not limited to, the group comprising lactose, dry lactose, lactose monohydrate, directly compressed lactose (lactose D.C.), starch, hydrolyzed starch, mannitol, sorbitol, xylitol, dextrose, dextrose monohydrate, dibasic calcium phosphate dihydrate, monobasic calcium, sulfate monohydrate, calcium sulfate dihydrate, amylose, calcium carbonate, glycine, bentonite.
  • compositions can be selected from, but not limited to, the group comprising sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, sugar esters of fatty acids and glycerides of fatty acids.
  • glidants can be selected from, but not limited to, the group comprising talc, silicone dioxide, magnesium trisilicate, cellulose powder, starch, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfates.
  • solubility modulators such as solubility modulators, sweeteners, coloring agents and coating agents can also be used in the formulation.
  • telmisartan, amlodipine and indapamide are turn into a pharmaceutical composition by conventional methods in the prior art.
  • the homogenous mixture obtained afterwards is dried and shaped as required.
  • Preparation of the bilayer tablet composed of a fast release and a constant release layer comprises the following steps:
  • the constant release layer is prepared.
  • indapamide constitutes 5% of total amount of substances and pharmaceutically acceptable excipients with polymers providing constant release characteristic in addition.
  • Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and sieved. They are mixed so as to provide homogeneity.
  • telmisartan a layer which comprises telmisartan, amlodipine and indapamide surrounding the constant release layer.
  • This layer is prepared according to conventional tablet production methods with the addition of all the active agents and pharmaceutically acceptable excipients.
  • the pharmaceutical composition comprises 5% indapamide; 10% amlodipine and 30% telmisartan of total substance amount. Afterwards, the homogenous mixture obtained is dried and shaped as required.
  • Both mixtures prepared are pressed as bilayer tablet by imposing an appropriate compressive force. Firstly, the constant release layer is pressed, then the fast release layer is pressed around it.
  • the tablet is coated with pharmaceutically acceptable coating materials.
  • indapamide there is 2,5% indapamide in proportion to total substance amount of the pharmaceutical formulation in the constant release layer which is the innermost layer of the tablet.
  • polymers such as hydroxypropyl methyl cellulose, microcrystalline cellulose are added.
  • Other excipients are also added into the pharmaceutical composition.
  • Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and then sieved. They are mixed so as to provide homogeneity.
  • the fast release layer surrounding the constant release layer comprises 5% indapamide, 10% amlodipine and 35% telmisartan in proportion to total substance amount of the pharmaceutical formulation.
  • Said active agents are mixed with pharmaceutically acceptable excipients.
  • Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and then sieved. They are mixed so as to provide homogeneity.
  • composition is pressed into tablet form such that the constant release layer is the inner layer while the fast release layer is the outer layer.
  • the tablet is coated with pharmaceutically acceptable coating materials.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison d'agents actifs antihypertenseurs; des procédés de préparation de cette combinaison; et l'utilisation de cette combinaison dans le traitement de l'hypertension, des maladies liées à l'hypertension et de diverses maladies cardiovasculaires.
PCT/TR2011/000153 2010-05-28 2011-05-27 Combinaison d'agents antihypertenseurs WO2011149438A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11729785.3A EP2575808A1 (fr) 2010-05-28 2011-05-27 Combinaison d'agents antihypertenseurs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/04315 2010-05-28
TR201004315 2010-05-28

Publications (1)

Publication Number Publication Date
WO2011149438A1 true WO2011149438A1 (fr) 2011-12-01

Family

ID=44310842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000153 WO2011149438A1 (fr) 2010-05-28 2011-05-27 Combinaison d'agents antihypertenseurs

Country Status (2)

Country Link
EP (1) EP2575808A1 (fr)
WO (1) WO2011149438A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107174570A (zh) * 2017-03-09 2017-09-19 苏州东瑞制药有限公司 一种溶出性能稳定的替米沙坦片及其制备方法
CN107375274A (zh) * 2017-07-25 2017-11-24 合肥华方医药科技有限公司 生物利用度提高的吲达帕胺药物组合物
WO2018138578A1 (fr) * 2017-01-25 2018-08-02 The George Institute for Global Health Compositions pour le traitement de l'hypertension
WO2019098540A1 (fr) * 2017-11-15 2019-05-23 Chong Kun Dang Pharmaceutical Corp. Formulation ayant une propriété hygroscopique et une vitesse de dissolution améliorées comportant du telmisartan ou son sel pharmaceutiquement acceptable
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
WO2020021341A1 (fr) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions pour le traitement de l'hypertension
US10723700B2 (en) 2015-08-12 2020-07-28 Incyte Corporation Salts of an LSD1 inhibitor
US10800779B2 (en) 2015-04-03 2020-10-13 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10968221B2 (en) 2014-07-10 2021-04-06 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11155532B2 (en) 2014-02-13 2021-10-26 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11247992B2 (en) 2014-02-13 2022-02-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2023001880A1 (fr) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Comprimé bicouche comprenant du telmisartan et de l'indapamide
EP4295839A1 (fr) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combinaison de valsartan et d'indapamide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565911A (en) 1968-03-06 1971-02-23 Science Union & Cie Disubstituted n-amino indoline compounds
EP0089167A2 (fr) 1982-03-11 1983-09-21 Pfizer Limited Dihydropyridines comme agents anti-ischaémiques et antihypertensifs, procédé pour leur production et compositions pharmaceutiques les contenant
EP0502314A1 (fr) 1991-02-06 1992-09-09 Dr. Karl Thomae GmbH Benzimidazoles, médicaments les contenant et procédé pour leur préparation
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
CN101450211A (zh) * 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
US20090275559A1 (en) * 2008-04-30 2009-11-05 Blue Note Pharmaceuticals, Inc. Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565911A (en) 1968-03-06 1971-02-23 Science Union & Cie Disubstituted n-amino indoline compounds
EP0089167A2 (fr) 1982-03-11 1983-09-21 Pfizer Limited Dihydropyridines comme agents anti-ischaémiques et antihypertensifs, procédé pour leur production et compositions pharmaceutiques les contenant
EP0502314A1 (fr) 1991-02-06 1992-09-09 Dr. Karl Thomae GmbH Benzimidazoles, médicaments les contenant et procédé pour leur préparation
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
CN101450211A (zh) * 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
US20090275559A1 (en) * 2008-04-30 2009-11-05 Blue Note Pharmaceuticals, Inc. Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200951, Derwent World Patents Index; AN 2009-K61164, XP002659209 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11247992B2 (en) 2014-02-13 2022-02-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11155532B2 (en) 2014-02-13 2021-10-26 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10968221B2 (en) 2014-07-10 2021-04-06 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US11401272B2 (en) 2015-04-03 2022-08-02 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10800779B2 (en) 2015-04-03 2020-10-13 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10723700B2 (en) 2015-08-12 2020-07-28 Incyte Corporation Salts of an LSD1 inhibitor
US11498900B2 (en) 2015-08-12 2022-11-15 Incyte Corporation Salts of an LSD1 inhibitor
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
US20190314383A1 (en) * 2016-11-15 2019-10-17 The George Institute for Global Health Compositions for the treatment of hypertension
US10799487B2 (en) 2017-01-25 2020-10-13 The George Institute for Global Health Compositions for the treatment of hypertension
WO2018138578A1 (fr) * 2017-01-25 2018-08-02 The George Institute for Global Health Compositions pour le traitement de l'hypertension
JP2020506180A (ja) * 2017-01-25 2020-02-27 ザ ジョージ インスティテュート フォー グローバル ヘルス 高血圧症の処置のための組成物
CN110545819A (zh) * 2017-01-25 2019-12-06 乔治全球健康研究院 用于治疗高血压的组合物
TWI825279B (zh) * 2017-01-25 2023-12-11 澳大利亞喬治全球健康研究所 用於治療高血壓之組合物
AU2018213147B2 (en) * 2017-01-25 2023-08-31 The George Institute for Global Health Compositions for the treatment of hypertension
US10322117B2 (en) 2017-01-25 2019-06-18 The George Institute for Global Health Compositions for the treatment of hypertension
CN116327958A (zh) * 2017-01-25 2023-06-27 乔治全球健康研究院 用于治疗高血压的组合物
EP4101454A1 (fr) * 2017-01-25 2022-12-14 The George Institute For Global Health Compositions pour l'utilisation dans le traitement de l'hypertension
US11478462B2 (en) 2017-01-25 2022-10-25 The George Institute for Global Health Compositions for the treatment of hypertension
US20180243278A1 (en) * 2017-01-25 2018-08-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN107174570A (zh) * 2017-03-09 2017-09-19 苏州东瑞制药有限公司 一种溶出性能稳定的替米沙坦片及其制备方法
CN107174570B (zh) * 2017-03-09 2019-11-05 苏州东瑞制药有限公司 一种溶出性能稳定的替米沙坦片及其制备方法
CN107375274A (zh) * 2017-07-25 2017-11-24 合肥华方医药科技有限公司 生物利用度提高的吲达帕胺药物组合物
WO2019098540A1 (fr) * 2017-11-15 2019-05-23 Chong Kun Dang Pharmaceutical Corp. Formulation ayant une propriété hygroscopique et une vitesse de dissolution améliorées comportant du telmisartan ou son sel pharmaceutiquement acceptable
WO2020021341A1 (fr) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions pour le traitement de l'hypertension
CN112770746A (zh) * 2018-07-26 2021-05-07 乔治全球健康研究院 用于治疗高血压的组合物
US11512064B2 (en) 2018-08-31 2022-11-29 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2023001880A1 (fr) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Comprimé bicouche comprenant du telmisartan et de l'indapamide
EP4295839A1 (fr) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combinaison de valsartan et d'indapamide

Also Published As

Publication number Publication date
EP2575808A1 (fr) 2013-04-10

Similar Documents

Publication Publication Date Title
EP2575808A1 (fr) Combinaison d'agents antihypertenseurs
US8673945B2 (en) Solid pharmaceutical composition comprising amlodipine and losartan
JP6068765B2 (ja) 薬学的複合製剤
JP2011500505A (ja) オルメサルタンメドキソミル及びアムロジピンの固形製剤
MX2009000131A (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina.
KR101272470B1 (ko) 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
AU2016366073A1 (en) Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
CN101966181A (zh) 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
JP5854371B2 (ja) カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
CN102114017A (zh) 包含氨氯地平和培哚普利的药物组合物及其应用
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
US20080026050A1 (en) Solid dose formulations of a thrombin receptor antagonist
JP2015003915A (ja) カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
US6333361B1 (en) Pharmaceutical composition containing zafirlukast
TWI674907B (zh) 包括ＨＭＧ-ＣｏＡ還原酶抑制劑及鈣通道阻斷劑之組合製劑
CN102018708A (zh) 包含氨氯地平和阿托伐他汀镁的药物组合物
CN102000075A (zh) 包含氨氯地平和阿托伐他汀钙无水物的药物组合物
RU2628538C2 (ru) Композиция, включающая амлодипин и лозартан, имеющая улучшенную стабильность
CN109481437B (zh) 一种氯沙坦钾药物制剂
JPWO2008078727A1 (ja) 溶出性の改善された医薬組成物
CN102805749A (zh) 包含氯吡格雷和阿司匹林的分散片
CN102038682A (zh) 含有氨氯地平和阿托伐他汀钙溶剂化物的药物组合物
CN102266559A (zh) 包含替米沙坦盐和钙离子拮抗剂的药物组合物
US20120165386A1 (en) Stable oral pharmaceutial composition of atorvastatin
WO2012050539A1 (fr) Composition pharmaceutique comprenant l'eplérenone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11729785

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011729785

Country of ref document: EP